AG真人官方

LogicMark, Inc. (LGMK) 鈥� Form 4 insider transaction dated 07/01/2025

Director Robert A. Curtis reported the grant of 2,500,000 stock options under Table II. The options:

• Exercise/Conversion Price: $0.004 per share (effectively near-zero cost).
• Date Exercisable: immediate on 07/01/2025.
• Expiration: 06/30/2035 (10-year term).
• Underlying security: common stock, one share per option.

The filing states the award was received as quarterly compensation for board service for the period ended 06/30/2025. After the transaction, Curtis beneficially owns 2.5 million derivative securities, held directly. No non-derivative share holdings were disclosed.

The Form 4 contains no sales, open-market purchases, or other equity movements, and no additional reporting persons.

Key takeaways for investors:

• The option strike price is far below LGMK鈥檚 recent trading range, implying high intrinsic value if exercised and potential dilution if converted.
• The grant strengthens director equity alignment, but shareholders should monitor aggregate option overhang and possible future exercises.
• With only a single insider involved and no cash transaction, the immediate financial impact is limited; materiality depends on LogicMark鈥檚 total share count, which is not provided in the filing.

Form 4 snapshot: Ryerson Holding Corporation (ticker RYI) disclosed that director Bruce T. Crawford acquired 334 shares of Ryerson common stock on 30 Jun 2025. The shares were granted at a stated price of $0 under the company鈥檚 Director Compensation Program and vested in full on the grant date.

After the transaction, Crawford directly owns 334 shares; no indirect holdings or derivative securities were reported. The filing indicates an 鈥淎鈥� (Acquired) transaction code and contains no sales, option exercises, or derivative activity. Because the grant is part of routine board compensation and involves a modest number of shares, the event is not expected to materially affect Ryerson鈥檚 share count, liquidity, or insider-ownership profile. Nonetheless, the additional equity modestly aligns the director鈥檚 economic interests with common shareholders.

Everi Holdings Inc. (EVRI) filed a Form 4 disclosing that director Secil Tabli Watson has disposed of her entire equity stake in connection with the company鈥檚 previously announced merger transaction.

• Date of disposition: 01-Jul-2025 (the merger鈥檚 effective time).
• Cash consideration: Each common share and each share underlying outstanding RSUs was converted into the right to receive $14.25 in cash, with no interest.
• Common stock: 1,000 shares disposed; post-transaction ownership: 0.
• Restricted stock units: Five separate RSU grants totaling 40,400 units (2,400 + 7,600 + 9,200 + 10,700 + 10,500) were cancelled for the same cash consideration.
• Result: Watson now reports no direct or indirect ownership; Everi became a wholly-owned subsidiary of Voyager Parent LLC at closing.

The filing confirms the consummation of the merger outlined in the July 26 2024 Agreement and Plan of Merger among Everi, IGT PLC, Spinco (an IGT subsidiary), and Voyager entities. All equity interests have been converted to cash, ending the reporter鈥檚 insider status under Section 16.

Ryerson Holding Corporation (RYI) director Court D. Carruthers filed a Form 4 disclosing receipt of 405 shares of Ryerson common stock on 30 June 2025. The shares were granted under the company鈥檚 Director Compensation Program, vested in full on the grant date and carry a stated price of $0, confirming they are a non-cash equity award rather than an open-market purchase.

After the grant, Carruthers鈥� direct beneficial ownership increases to 4,958 shares. No derivative securities, dispositions, or additional transactions were reported. The award size is immaterial relative to Ryerson鈥檚 share count and therefore unlikely to influence valuation or trading dynamics. Nevertheless, incremental share accumulation marginally aligns the director鈥檚 interests with those of shareholders.

Ryerson Holding Corp. (RYI) Form 4 filing: Director Kirk K. Calhoun reported the receipt of 405 shares of common stock on 30 June 2025 under the company鈥檚 Director Compensation Program. The equity award vested immediately and was granted at $0 cost to the director. Following the transaction, Calhoun鈥檚 direct ownership rises to 3,458 shares. No derivative securities or sales were disclosed in this filing.

The transaction is routine, reflects standard annual board compensation, and does not signal any change in the company鈥檚 fundamentals or insider sentiment beyond a modest increase in insider ownership.

Ryerson Holding Corporation (RYI) 鈥� Form 4 insider filing

Chief Operating Officer Michael Burbach reported three separate awards of dividend-equivalent restricted stock units (RSUs) on 18 Jun 2025. These RSUs automatically accumulate when cash dividends are paid on previously granted, unvested RSUs and carry no cash cost to the insider.

• 37.201 RSUs tied to the March 31 2023 grant; vesting 31 Mar 2026.
• 51.974 RSUs tied to the March 31 2024 grant; vesting 31 Mar 2026-2027.
• 20.222 RSUs tied to the March 31 2025 grant; vesting 31 Mar 2026-2028.

Total additional RSUs: 109.397, increasing Burbach鈥檚 direct holdings within each referenced award tranche to 4,116.411; 5,750.995; and 2,237.529 units, respectively. No common shares were sold, and the transaction code is 鈥淎鈥� (acquired) with a stated price of $0, indicating purely stock-settled, dividend-equivalent accruals.

The filing is routine, aligns management incentives with shareholders, and does not materially change Ryerson鈥檚 share count or insider ownership structure.

Ryerson Holding Corporation's Chief Information Officer Alagu Sundarrajan received dividend equivalent rights on existing restricted stock units (RSUs) on June 18, 2025. The transactions include:

• 18.601 RSUs from March 2023 grant, vesting March 31, 2026
• 36.384 RSUs from March 2024 grant, vesting in two tranches through March 31, 2027
• 60.19 RSUs from March 2025 grant, vesting in three tranches through March 31, 2028

These dividend equivalent rights accrue when dividends are paid on common shares and vest according to the same schedule as their underlying RSUs. Following these transactions, Sundarrajan beneficially owns 2,058.206 RSUs from the 2023 grant, 4,026.001 RSUs from the 2024 grant, and 6,660.19 RSUs from the 2025 grant, all held directly. The dividend equivalents were granted at $0 cost to the executive.

Form 4 Overview: Maravai LifeSciences Holdings, Inc. (MRVI) disclosed that director John A. DeFord acquired 89,139 shares of Class A common stock on 16 June 2025.

Transaction details: The shares were granted as restricted stock units (RSUs) under the company鈥檚 2020 Omnibus Incentive Plan at an assigned value of $2.16 per share. These RSUs will vest in full on the earlier of (i) one year from the grant date or (ii) the date of the 2026 annual shareholder meeting.

Post-transaction ownership: Following the award, DeFord鈥檚 beneficial ownership rises to 159,185 shares, all held directly.

Implications: A director increasing his stake鈥攁lbeit via equity compensation鈥攖ends to align management and shareholder interests and can be interpreted as a vote of confidence in MRVI鈥檚 long-term prospects. Because the grant stems from an incentive plan rather than an open-market purchase, any cash outlay by the insider is not indicated in the filing.